Key Highlights
- Shares jumped in the stock's strongest single session in more than seven months
- Revenue for H1 2026 rose 10.5% to £116.7m, with gross Margin up 400 basis points to 62.2%
- The adjusted EBITDA loss narrowed to £22.1m from £48.3m, and net loss fell to £48.0m from £71.8m
- Management reiterated a target of adjusted EBITDA breakeven in FY27 and positive free Cash Flow in FY28
- Cash, cash equivalents and liquid investments stood at £234.5m at the half-year, down from £302.8m
The Oxford-based sequencing group put in its best Trading session in more than seven months after half-year results showed gross margin climbing sharply and losses more than halving — giving investors fresh confidence in a maiden year of adjusted profitability in 2027.
A results-day rerating
Shares in Oxford Nanopore Technologies (LSE:ONT) jumped after the genomic-sequencing company published interim results on 19 August 2026, in what several commentators described as the stock's strongest single session in over seven months. The move extended over subsequent sessions as investors digested numbers that spoke directly to the question hanging over the Business since its 2021 flotation: when, and how, it stops burning cash.
The rally is notable because it was driven less by headline Revenue — which grew at a more modest pace than in recent years — and more by the quality of the progress underneath. A 400 basis-point improvement in gross margin, an adjusted EBITDA loss that more than halved, and a firmly reiterated target of adjusted EBITDA breakeven in the 2027 financial year combined to reassure a Shareholder base grown weary of persistent losses. For a company whose case rests on the transition from cash-consuming growth story to self-funding technology platform, the direction of travel matters more than any single quarter's top line.
What the numbers showed
Revenue for the six months to 30 June 2026 came in at £116.7m, up 10.5% as reported and 12.3% on a constant-currency basis from £105.6m a year earlier. Momentum will be supported in the second half by a licensing arrangement with an undisclosed global diagnostics partner, expected to generate around $20m of licensing fees, alongside roughly $15m of committed product purchases across FY27–FY28.
The standout was profitability. Gross margin rose to 62.2% from 58.2%, a 400 basis-point gain management attributed to stronger Demand in its EMEAI region and in the higher-value biopharma and clinical segments, together with tighter cost control. The adjusted EBITDA loss narrowed to £22.1m from £48.3m, and the net loss fell to £48.0m from £71.8m. Operating costs declined by close to 7% year on year.
Segment performance was uneven. Clinical revenue rose around 35% and biopharma grew about 25%, while sales into China fell close to 16% — a reminder that regional headwinds remain live. Cash, cash equivalents and liquid investments stood at £234.5m at the half-year, down from £302.8m at the end of December 2025, reflecting continued but slowing cash consumption.
A new chief executive sharpens the focus
The results were the first full set delivered under Francis Van Parys, who became chief executive on 2 March 2026, succeeding founder Gordon Sanghera. Van Parys arrived from Radiometer, a Danaher-owned diagnostics business, bringing more than two decades of senior life-sciences experience; Sanghera, who founded the Oxford spin-out in 2005, remains in an advisory role through early 2027.
Van Parys has used his opening months to narrow the commercial emphasis onto three markets judged closest to scale: mRNA Vaccine quality control, methylation study within genome sequencing, and leukaemia diagnostics. That focus, paired with the improved margin trajectory, appears to have been what excited the market. Management reaffirmed a longer-term ambition of exceeding $700m of annual revenue by 2030 at an adjusted EBITDA margin above 15%, and framed a run to $1bn of revenue as a milestone beyond that horizon.
Guidance and the road to breakeven
For the full 2026 financial year, Oxford Nanopore guided to constant-currency revenue growth of 16–20% excluding the licensing revenue, or 23–27% including it, with gross margin of around 62% (or roughly 64% with the licensing contribution). Adjusted operating costs are expected to be flat to slightly down. Crucially, the board held firm on its profitability roadmap: adjusted EBITDA breakeven in FY27, followed by positive free cash flow in FY28.
The context from 2025 helps frame the improvement. The company reported full-year 2025 revenue of £223.9m, up 22.2%, with the adjusted EBITDA loss narrowing 31.2% to £86.7m. The half-year data suggest that improvement is accelerating rather than stalling, which is why the breakeven target now reads as more credible than aspirational. Berenberg, which maintained a Buy rating while trimming its price target to £2.00 from £2.20 on regional revenue headwinds, described the company as comfortably on track to reach breakeven by 2027.
What could drive the shares next
Several evidence-based catalysts could shape sentiment from here. Continued gross-margin expansion is the clearest: each further step towards the mid-60s range shortens the distance to breakeven and reduces reliance on external funding. Delivery on the higher-margin clinical and biopharma pipelines — the segments already growing fastest — would reinforce the mix shift that underpins the margin story.
Execution on the new licensing model is another potential lever. If the diagnostics Partnership signed this year proves a template for further royalty-bearing deals, it could add revenue at attractive margins without a commensurate rise in cost. Progress in the three prioritised clinical applications may also act as discrete catalysts. Finally, favourable developments in the group's intellectual-property litigation against MGI and BGI entities — where MGI has conceded in Australia that its Cyclone SEQ WT02 device infringes four of Oxford Nanopore's patents, with a trial slated for 2027 — could remove an overhang.
Risks investors should watch
The Investment case is not without genuine hazards. The company is still loss-making and consuming cash, and although Liquidity of £234.5m provides a runway, the breakeven target for 2027 leaves limited room for slippage should growth disappoint. Revenue growth has decelerated from the pace of prior years, and part of the reported figure now leans on one-off licensing income rather than recurring product sales.
Regional exposure is a real risk: the near-16% decline in Chinese sales, alongside softness Berenberg flagged in the Middle East, shows how quickly geography can offset progress elsewhere. The IP litigation, while so far tilting the company's way, carries cost and uncertainty. And as a technology platform competing against far larger sequencing rivals, Oxford Nanopore must keep innovating to protect the very margins that drove this rerating.
Investor takeaway
The August results marked a turning point in perception rather than a single transformative event. By showing margin expansion, halving losses and holding its nerve on breakeven guidance, Oxford Nanopore Technologies (LSE:ONT) gave the market a reason to look past decelerating headline growth towards a genuinely self-funding future. A focused new chief executive and a clearer commercial narrative added to the shift in tone.
What investors will watch from here is consistency: whether margins keep climbing, whether the clinical and biopharma segments sustain their momentum, and whether the 2027 breakeven promise survives contact with softer regions and a maturing product cycle. The surge reflects genuine operational progress, but the target now set — profitability within roughly eighteen months — leaves little margin for error in delivering it.






Please wait processing your request...